Abstract
Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this treatment induces complete remissions in the majority of patients, many face a relapse (adaptive resistance) or have refractory disease (primary resistance). Moreover, older patients are often unfit for cytotoxic-based treatment. AML relapse is due to the survival of therapy-resistant leukemia cells (minimal residual disease, MRD). Leukemia cells with stem cell features, named leukemic stem cells (LSCs), residing within MRD are thought to be at the origin of relapse initiation. It is increasingly recognized that leukemia “persisters” are caused by intra-leukemic heterogeneity and non-genetic factors leading to plasticity in therapy response. The BCL2 inhibitor venetoclax, combined with hypomethylating agents or low dose cytarabine, represents an important new therapy especially for older AML patients. However, often there is also a small population of AML cells refractory to venetoclax treatment. As AML MRD reflects the sum of therapy resistance mechanisms, the different faces of treatment “persisters” and LSCs might be exploited to reach an optimal therapy response and prevent the initiation of relapse. Here, we describe the different epigenetic, transcriptional, and metabolic states of therapy sensitive and resistant AML (stem) cell populations and LSCs, how these cell states are influenced by the microenvironment and affect treatment outcome of AML. Moreover, we discuss potential strategies to target dynamic treatment resistance and LSCs.
Highlights
The major problem with cancer treatment is that many patients obtain impressive remissions after a wide variety of treatments yet retain residual tumor cells after the initial therapy, which can develop into recurrence or metastasis
acute myeloid leukemia (AML) “persisters” (MRD) after initial therapy are caused by various mechanisms that co-exist, including epigenetic, transcriptional, and metabolic processes
Increasing the knowledge on the mechanisms driving this persistence, and on the changes in identity of MRD and leukemic stem cells (LSCs) during the course of the disease is crucial for the development of successful therapeutic strategies to overcome therapy resistance and to inhibit leukemia-initiating potential
Summary
The major problem with cancer treatment is that many patients obtain impressive remissions after a wide variety of treatments yet retain residual tumor cells after the initial therapy, which can develop into recurrence or metastasis. The poor treatment outcome of AML is in part of the patients due to refractoriness to chemotherapy at diagnosis but in the major part caused by relapse originating from a small subpopulation of therapy-resistant leukemia cells (minimal residual disease, MRD) [2, 3] (Figure 1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have